Curriculum Vitaes
Profile Information
- Affiliation
- School of Medicine Faculty of Medicine, Department of Advanced Endoscopy (formerly Department of Gastroenterology), Fujita Health University
- Degree
- 博士(医学)
- J-GLOBAL ID
- 200901011108502975
- researchmap Member ID
- 6000005568
患者さんの立場にたって、安全かつ最高の医療を提供できるよう努力します。
Research Interests
10Research Areas
1Committee Memberships
28-
Jul, 2023 - Present
-
- Present
Awards
4-
May, 2000
Papers
280-
Journal of gastroenterology, Nov 18, 2025BACKGROUND: Owing to the rarity of metastatic tumors in the small bowel, their clinicopathological features, and prognostic factors remain poorly understood. This study aimed to clarify the clinicopathological features and factors associated with the prognosis of patients with small bowel metastasis from other organs in Japan. METHODS: We retrospectively examined 253 patients who were histopathologically diagnosed with small bowel metastases between January 2008 and December 2017 at multiple institutions in Japan. We identified the clinicopathological features of the condition and determined the factors associated with the prognosis of these patients. RESULTS: Obstructive symptoms were the most frequent clinical presentations (39% abdominal pain and 18% vomiting), while gastrointestinal bleeding was observed in 27% of patients. The diagnostic modalities included enteroscopy (33%), balloon-assisted enteroscopy (30%), and capsule endoscopy (13%). The most common primary tumor was lung cancer (38%), followed by colorectal cancer (18%), gastric cancer (9%), and malignant melanoma (6%). Surgical intervention, including tumor resection or bypass surgery, was performed in 79% of patients. The cumulative survival rates of patients at 12, 24, and 60 months were 49%, 36%, and 22%, respectively. Multivariate analysis identified surgery as a significant factor for improving overall survival (HR = 0.56, 95% CI 0.35-0.89, p = 0.01). CONCLUSIONS: The lung cancer is the most frequent primary tumor of metastatic tumors in the small bowel. Surgical intervention was associated with improved survival outcomes.
-
Journal of gastroenterology, Oct 22, 2025BACKGROUND: Peutz-Jeghers syndrome (PJS), a rare genetic disorder characterized by hamartomatous gastrointestinal polyps, poses increased risks of various cancers. Despite the importance of early intervention, the optimal timing for jejunal-ileal polypectomy remains unclear owing to the limited number of comparative studies. METHODS: Herein, we conducted a nationwide survey in Japan and analyzed data from 184 patients with PJS identified through a two-stage sampling process. The initial screening of 2912 medical institutions yielded 1748 facilities, of which 1077 responded to the survey. Time-dependent Cox proportional hazards models and logistic regression analyses were used to examine the association between the timing of jejunal-ileal polypectomy and the risk of surgery for intussusception. RESULTS: Among 184 patients (47.0% women; mean age, 33.5 years), intussusception was the most common complication (67.7%). In the Cox proportional hazards analysis excluding surgeries within 1 year of diagnosis, early jejunal-ileal polypectomy was associated with a reduced risk of surgery for intussusception (adjusted hazard ratio, 0.17; 95% confidence interval [CI] 0.04-0.74, p = 0.018). Logistic regression analysis showed higher odds of surgery in the late treatment group compared with the early treatment group (adjusted odds ratio, 4.26; 95% CI 1.38-13.16, p = 0.012). CONCLUSIONS: Early jejunal-ileal polypectomy may reduce the risk of intussusception in patients with PJS. However, the need for frequent endoscopic procedures must be balanced considering patient burden. These findings support the importance of early intervention and highlight the need for optimized surveillance strategies that consider clinical effectiveness and patients' quality of life.
-
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 23(11) 1991-2000, Oct, 2025BACKGROUND & AIMS: Although biologic therapy has revolutionized the treatment of Crohn's disease (CD), surgery remains unavoidable in cases involving ileal complications. We aimed to evaluate the efficacy of biologics on proximal ileal lesions using balloon-assisted enteroscopy (BAE). METHODS: This open-label multicenter prospective study was conducted at tertiary referral centers in Japan. We enrolled 253 patients with active ileal CD who were treated with biologics (infliximab/adalimumab/ustekinumab/vedolizumab). BAE was performed at week 0 and week 26, and endoscopic findings were centrally assessed. We evaluated the rate of endoscopic remission (defined as having a maximum modified Simple Endoscopic Score for Crohn's disease <4) at week 26 and patient prognosis (CD-related hospitalization and surgery). RESULTS: At baseline, 74 patients (29.2%) had proximal ileal ulcerations without terminal ileal ulcerations. The second BAE showed that endoscopic remission was achieved in 91 patients (36.0%). Of the patients with complete ulcer healing of the terminal ileum, 28.6% (22/77) had residual ulcers in the proximal ileum. The rate of endoscopic remission in the proximal ileum (50.9%) was relatively lower compared with the colon (63.4%) and terminal ileum (56.7%), a trend consistently observed across all treatment agents. After a median follow-up of 134 weeks, residual ulcerations in the proximal ileum were associated with a poorer prognosis (P = .0126 for hospitalization and P = .0014 for surgery). CONCLUSIONS: A substantial proportion of patients with CD exhibited ulcerations in the proximal ileum, which correlated with a poorer prognosis. These lesions proved challenging to heal, regardless of the type of biologic used.
-
Journal of gastrointestinal and liver diseases : JGLD, 34(3) 407-408, Sep 26, 2025
-
JGH open : an open access journal of gastroenterology and hepatology, 9(7) e70209, Jul, 2025AIMS: The Japan COVID-19 Survey and the Questionnaire for Inflammatory Bowel Disease (J-DESIRE) identified multiple factors associated with anxiety regarding the novel coronavirus disease 2019 (COVID-19). However, no regional differences in anxiety were observed. In this post hoc analysis of J-DESIRE, we investigated the relationship between the municipal population size at the place of residence (MPSPR) and anxiety among patients with IBD in Japan during the COVID-19 pandemic. METHODS AND RESULTS: We analyzed 2958 questionnaires collected from patients with IBD aged ≥ 16 years between March 2020 and June 2021. The primary endpoint was the association between the visual analogue scale (VAS) scores of anxiety and MPSPR during the COVID-19 pandemic. The mean VAS score for anxiety was higher than the overall mean VAS score in municipalities with large and small populations, while it was lower in municipalities with medium populations. Therefore, we categorized the population into three groups based on MPSPR: ≤ 150 000, 150 001-1 000 000, and ≥ 1 000 001. The three groups had different background factors, contents of anxiety, and sources of information regarding therapeutic drugs. These differences may have led to differences in the degree and content of anxiety. CONCLUSIONS: We investigated the association between anxiety in Japanese patients with IBD and MPSPR nationwide during the COVID-19 pandemic in Japan. The results obtained in this analysis are useful not only in special situations such as the COVID-19 pandemic but also for considering regional differences in medical care.
Misc.
1301-
日本臨床, 70(増刊1 炎症性腸疾患) 218-224, Feb, 2012
-
Gastroenterological Endoscopy (0387-1207)54巻, 54(Suppl.1) 1086-1086, 2012
-
肝胆膵, 65(2) 377-383, 2012EUS-elastography(EUS-EG)による膵線維化診断について検討した。術前に腫瘍尾側膵に対しEUS-EGを施行し、その4週間以内に腫瘍を含めた膵切除術を実施した58例を後ろ向きに検討した。膵線維化の進行に伴うグレースケールヒストグラムの形状変化では、膵線維化の進行に伴い、ヒストグラムの平均値は小さくなり、形状はグレースケール値の小さい方向に歪み、裾野は長くなる傾向を認めた。膵線維化の進行により、腫瘍尾側膵のEUS-EG画像は硬く不均一になるものと考えられた。
-
消化器内科, 55(1) 102-108, 2012超音波内視鏡(EUS)で診断し、12ヵ月以上経過観察できた分岐型膵管内乳頭粘液性腫瘍(IPMN)患者170例(男性95例、女性75例、平均64.7歳)と慢性膵炎患者108例(男性85例、女性23例、平均59.8歳)を対象に、膵癌発生頻度を算出した。分岐型IPMNの平均観察期間は50.4ヵ月で、6例(3.5%)に膵癌発生を認め、Kaplan-Meier法による膵癌発生頻度は5年発生率2.9%であり、標準化膵癌発生比(SIR)は19.6であった。6例中3例は切除不能(癌性腹膜炎2例、多発肝・肺転移1例)の病期で診断された。慢性膵炎の平均観察期間は60.7ヵ月で、3例(2.8%)に膵癌発生を認め、Kaplan-Meier法による膵癌発生頻度は5年発生率2.4%であり、SIRは26.2であった。3例とも膵石を認め、1例は切除不能(血管侵襲+)で、基礎疾患に慢性腎不全を持ち、CTにて経過観察されており、癌性腹水を契機に診断された。
-
消化器医学, 9 70-76, Dec, 2011大腸カプセル内視鏡における新しい腸管前処置方法について検討した。被験者にかかる負担を少なくした腸管前処置方法(1日法)と、従来から海外で用いられている方法(2日法)と比較検討した。1日法に31例、2日法に29例を無作為に割りつけた。全症例とも規定の下剤を服用できた。バッテリー時間内にカプセルが体外に排出された割合は1日法で71%、2日法で55%であった。1日法のうち、大腸内視鏡検査予定患者は4例で、全例がバッテリー時間内にカプセルは体外に排出された。1日法のうち、無症状健常ボランティアは27例で、そのうちバッテリー時間内にカプセルが体外に排出したのは18例であった。2日法のうち、大腸内視鏡検査予定患者は4例で、バッテリー時間内にカプセルが体外に排出したのは3例であった。2日法のうち、無症状健常ボランティアは25例で、そのうちバッテリー時間内にカプセルが体外に排出したのは13例であった。
-
消化器内科, 53(6) 712-717, Dec, 2011造影超音波内視鏡検査(CE-EUS)による膵癌と自己免疫性膵炎(AIP)の鑑別診断法は、EUSで画像観察を行い、病変描出後に超音波造影剤Sonazoidを静注し、デジタルデータは造影開始から連続1分間、3分後と5分後は20秒間ずつを保存した。検査終了後にデジタルデータを再生しながら病変部にROIを設定し、time-intensity curve(TIC)を作成した。TIC作成によりecho-intensityが数字化され、定量的解析が可能であった。膵管癌では、造影早期に屈曲した広狭不整な異常血管を伴い、淡く不均一な造影効果を認めることが多く、TICでは多くの症例でecho-intensityの造影剤注入前からピークへの増加率は他の膵疾患と類似の値を取るが、ピークの持続時間が短く、1分以内に速やかな低下が描かれた。AIPでは、CE-EUSイメージは病変全体が均一に造影され、造影カラードプラーでは腫瘤が周囲膵組織に比べisovascularであることが確認でき、TICはほぼプラトーであった。
-
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 26 253-253, Oct, 2011
-
Pancreas, 40(7) 1073-9, Oct, 2011 Peer-reviewed
-
AJR. American journal of roentgenology, 197(4) 867-75, Oct, 2011 Peer-reviewed
-
Gastroenterological Endoscopy, 53(Suppl.2) 2419-2419, Sep, 2011
-
Gastroenterological Endoscopy, 53(Suppl.2) 2455-2455, Sep, 2011
-
Gastroenterological Endoscopy, 53(Suppl.2) 2475-2475, Sep, 2011
Books and Other Publications
49-
羊土社, Oct 15, 2024 (ISBN: 9784758110853)
Presentations
446-
第16回日本炎症性腸疾患学会学術集会, Aug 22, 2025
-
第109回日本消化器内視鏡学会総会, May 9, 2025
-
第111回日本消化器病学会総会, Apr 25, 2025
Teaching Experience
7Professional Memberships
12Research Projects
31-
Grants-in-Aid for Scientific Research, Japan Society for the Promotion of Science, Apr, 2022 - Mar, 2025
-
Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C), Japan Society for the Promotion of Science, Apr, 2022 - Mar, 2025
-
Advanced medical care B, Ministry of Health, Labour and Welfare, Feb, 2021 - Jun, 2024
-
令和6年度 医療機器等研究成果展開事業(開発実践タイプ), 国立研究開発法人日本医療研究開発機構(AMED), Jun, 2024
-
令和3年度難治性疾患実用化研究事業, 国立研究開発法人日本医療研究開発機構(AMED), May, 2021 - Mar, 2024